Clinical trials
Phase 2/3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 2 |
| 2014 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Terminated | 2 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amneal Pharmaceuticals, LLC | 1 |
| Ann & Robert H Lurie Children's Hospital of Chicago | 1 |
| Bristol-Myers Squibb | 1 |
| Gamida Cell -Teva Joint Venture Ltd. | 1 |
| Gruppo Italiano Trapianto di Midollo Osseo | 1 |
| Hoffmann-La Roche | 1 |
| M.D. Anderson Cancer Center | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Novartis Pharmaceuticals | 1 |
| Rambam Health Care Campus | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 12 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
| Leukemia, Myeloid, Acute | 4 |
| Leukemia | 2 |
| Myelodysplastic Syndromes | 2 |
| Anemia, Refractory, with Excess of Blasts | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Carcinoma, Renal Cell | 1 |
| Gastrointestinal Stromal Tumors | 1 |
| Hematologic Neoplasms | 1 |
Trials
Showing 1 to 12 of 12. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.